Since 2017 6 CAR-T therapies have been approved by the FDA. Over 500 clinical trials involving CAR-T are ongoing and the $2Bn market is expected to grow at over 35% year over year. It is an incredibly promising class of therapy for cancer treatment. Yet, many candidate therapies see disappointing response rates in clinical trials – perhaps resulting from poorly engineered (or non engineered) T-cells persisting in the administered product and causing a conflict with the patient’s immune system. Many teams are therefore working on methods to better enrich and purify engineered t-cells.
Known, high-performing and well used antibodies against useful targets on CAR-T cells can be examined for mechanism of action using proteomics and mass spectrometry. Knowledge of the antibody sequences via Next Generation Protein Sequencing (NGPS) can be useful for humanizing or otherwise engineering constructs. Rapid Epitope mapping by HDX can be useful for both epitope and paratope engineering strategies.